CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Folate Testing Coverage Policy

Coverage policy for laboratory testing of folate (serum, RBC, folate receptor autoantibodies) including indications and limitations for BlueCross BlueShield of Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyFolate Testing Coverage Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDocument diagnosis of megaloblastic or macrocytic anemia and prior folic acid treatment without resolution when ordering serum folate.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1covered indication count

RBCRBC folate not covered

FRATFRAT not covered

ASCP CWguideline cited

3procedure codes listed

Coverage criteria — when folate testing is covered

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Serum folate - covered indication

Covered when ALL of the following are met

Serum folate coverage: Individual has megaloblastic or macrocytic anemia AND the megaloblastic anemia and/or macrocytosis does not resolve after folic acid treatment

Serum folate measurement meets coverage criteria only in this scenario

inv-02: Not medically necessary / Not covered

Not covered tests: Measurement of serum folate for indications other than described above; measurement of red blood cell (RBC) folate for all indications; folate receptor autoantibody testing for all situations

These tests DO NOT MEET COVERAGE CRITERIA

inv-03: Supported Indications

Covered when aligned with specialty guideline indications

Situations where RBC folate or serum folate testing is supported: - Suspected folate deficiency when serum folate is equivocal or recent dietary intake may obscure deficiency (guideline sources). - Unexplained macrocytic/megaloblastic anemia after initial evaluation and when vitamin B12 is not deficient. - Preoperative bariatric surgery assessment and postoperative surveillance per bariatric perioperative nutrition guidelines. - Patients with IBD, celiac disease, or small bowel resection at risk for deficiency; measure at least annually or when macrocytosis present. - Initial evaluation for myelodysplastic syndromes where RBC folate is preferred by NCCN as part of the workup.

Selection between serum vs RBC folate depends on clinical context and guideline preference; RBC preferred for MDS per NCCN.

Folate receptor autoantibody testing (proprietary assays such as FRAT®) is not covered for any indication. The policy specifies that these tests do not meet coverage criteria due to insufficient published scientific evidence demonstrating clinical benefit or necessity.

Routine ordering of red blood cell (RBC) folate in adults is discouraged. The ASCP/Choosing Wisely guidance (2017) advises against ordering RBC folate levels and recommends considering folate supplementation instead of routine testing in adults with macrocytic anemia given the low prevalence of deficiency after folic acid fortification.

Professional guidance cited in the policy recommends against routine RBC folate testing in many adult populations and suggests that folate supplementation may be an appropriate initial management approach. These recommendations reflect evidence-based statements and guideline reviews included in the policy's reference list.

The policy considers routine RBC folate testing in adults without a specific clinical indication to be not medically necessary. Professional societies referenced in the policy advise against routine ordering of RBC folate and recommend a therapeutic trial of folic acid in many cases before pursuing specialized testing.

Ordering RBC folate as a routine laboratory test in adults without supporting clinical indications is unnecessary per cited guidance. The AAFP and other societies emphasize targeted testing only when clinical context (for example, persistent macrocytosis or suspected malabsorption) warrants measurement rather than routine screening.

Several references and position papers cited in the policy state that folate assays may be unjustified for routine anemia workups in countries with mandatory folic acid food fortification. The historical and evidence-based literature on folic acid fortification and its impact on deficiency prevalence is included in the policy bibliography.

Indications where testing may be covered

inv-30: Persistent megaloblastic or macrocytic anemia not resolving after folic acid treatment

Serum folate measurement meets coverage criteria in this indication

Persistent megaloblastic or macrocytic anemia not resolving after folic acid treatment: Measurement of serum folate is ordered for an individual with documented megaloblastic or macrocytic anemia and there is documentation that the anemia and/or macrocytosis did not resolve after an adequate trial of folic acid supplementation.

Documentation must support diagnosis and prior folic acid treatment without resolution.

inv-32: Testing for folate status (serum or RBC) when clinically indicated; folate receptor autoantibodies per proprietary test description

Clinical guidelines inform appropriate use; proprietary folate receptor antibody testing (FRAT®) is described but not supported by evidence for general coverage

Guideline‑aligned testing options: Testing for folate status (serum folate or RBC folate) when clinically indicated per specialty guidelines (eg, bariatric perioperative screening, IBD/malabsorption surveillance, equivocal serum folate results) OR testing for folate receptor autoantibodies (0399U/FRAT®) only when evaluation for suspected cerebral folate deficiency is performed and the proprietary test description and clinical context are documented.

Policy cites guideline preference for RBC folate in certain contexts (eg, MDS) but restricts routine RBC folate ordering; FRAT® is a proprietary assay (0399U) and lacks sufficient evidence for broad coverage.

Tests and uses that do not meet coverage

Red blood cell (RBC) folate testing and folate receptor autoantibody testing are explicitly listed as not covered for all indications. The policy states these tests do not meet coverage criteria for any indication and are therefore excluded from coverage.

The ASCP/Choosing Wisely recommendation is cited to support the policy position that routine RBC folate testing in adults without specific clinical indications is not supported and may be excluded from coverage.

The policy references evidence and position papers noting that in regions with folic acid food fortification, routine folate assays for anemia investigation may no longer be justified. This literature informs the policy's stance that routine RBC folate testing is often unnecessary.

Provider actions, documentation, and billing notes

Documentation Required

Provider actions, documentation, and billing notes

Prior authorization may be required per the member's benefit plan. Measurement of serum folate is covered only for individuals with megaloblastic or macrocytic anemia that does not resolve after a therapeutic trial of folic acid; all other indications for serum folate are not covered. Measurement of RBC folate is generally not covered except when documentation supports its use (for example, as part of an initial myelodysplastic syndrome evaluation with supporting MDS workup documentation). Testing performed for bariatric perioperative screening or for patients with documented malabsorption risks may be considered when accompanied by appropriate clinical documentation. Laboratory-developed tests (LDTs) must be validated and performed in CLIA-regulated high-complexity laboratories; include validation information when requested. Denials may be issued for routine or screening use of serum or RBC folate, for folate receptor autoantibody testing, and for any indication lacking supporting clinical documentation.

Covered indication — serum folate: megaloblastic/macrocytic anemia not resolving after folic acid trial (document therapeutic trial and persistent findings).
Not covered — serum folate for indications other than above; RBC folate not routinely covered.
RBC folate: may be considered when ordering for initial MDS evaluation with documentation of MDS workup per NCCN.
Bariatric/perioperative testing: preoperative screening (iron studies, B12, folate/RBC folate) may be appropriate when documented per bariatric guidelines; include clinical indication and risk factors (malabsorptive procedures, childbearing potential, pregnancy surveillance).
Therapeutic trial: consider or document a trial of folic acid supplementation in adults with macrocytic anemia prior to ordering testing, per ASCP/Choosing Wisely recommendations.
Concurrent evaluation: document assessment of vitamin B12 status when evaluating folate (use RBC folate when serum folate is equivocal or dietary intake/malabsorption is a concern), per specialty society guidance.
LDT/CLIA: provide laboratory validation evidence for in-house LDTs if requested; LDTs are high-complexity under CLIA.
Denial triggers: routine assessment without clinical indication, ordering for unsupported indications, missing documentation of failed therapeutic trial, lack of B12 evaluation when indicated, and conflicts with applicable government (LCD/NCD/Medicaid) policies.

What to include when ordering folate testing

Documentation Required

Ordering requirement — document anemia and failed folic acid therapy

Document the diagnosis of megaloblastic or macrocytic anemia and prior folic acid treatment without resolution when ordering serum folate to support medical necessity.

Include prior folic acid therapy details and objective evidence of persistent anemia/macrocytosis.

Documentation Required

Ordering requirement — document clinical context and risk factors

When ordering folate testing, document relevant clinical context such as presence of macrocytosis, suspected malabsorption, bariatric surgery status, or CKD-related anemia evaluation to justify the test.

For bariatric patients, reference preoperative checklist or postoperative surveillance plan.
For patients with suspected malabsorption, document small bowel disease/resection or related risk factors.

Documentation Required

Ordering requirement — LDT validation and in-house performance (CLIA high-complexity)

Laboratory-developed tests must be validated and performed in-house by appropriately certified laboratories; LDTs are regulated as high-complexity under CLIA and FDA clearance is not required for clinical use.

Ensure the performing laboratory maintains CLIA high-complexity certification and retains validation records for LDTs.

Definitions and test descriptions

Megaloblastic anemia — definition and clinical features

DefinitionMegaloblastic anemia: a specific macrocytic anemia due to defects in nucleic acid metabolism causing nuclear–cytoplasmic dyssynchrony and abnormal marrow precursors (commonly from folate and/or B12 deficiency)

Typical featuresMacrocytosis (elevated MCV), abnormal peripheral smear with megaloblastic changes, low reticulocyte response in active disease

Common symptomsWeakness, fatigue, difficulty concentrating, irritability, headache, palpitations, and shortness of breath

Serum folate — definition

DefinitionSerum folate: measurement of folate concentration in serum that primarily reflects recent dietary intake and can be affected by transient changes

Clinical implicationMay not distinguish transient reduction in intake from chronic deficiency; can be used as an initial screen per some studies

Relationship to RBC folateCorrelates with hepatocyte folate and can align with RBC folate, but is more influenced by recent intake

RBC folate — definition

DefinitionRBC folate: folate concentration within erythrocytes reflecting folate status over the ~120‑day lifespan of red blood cells

Clinical implicationLess influenced by acute dietary fluctuations and better reflects longer-term folate stores

Use caseMay be preferred when chronic deficiency is suspected or when serum folate is equivocal

Red blood cell folate — short label

Short labelRed blood cell folate (RBC folate)

NoteReflects longer-term folate status (≈120‑day RBC lifespan)

GuidanceRoutine RBC folate testing in adults is discouraged by ASCP Choosing Wisely unless specific indications exist

Serum folate — short label

Short labelSerum folate (folic acid)

NoteReflects recent intake and may fluctuate with diet

UseOften used as an initial screening test; may be misleading if recent intake obscures chronic deficiency

Laboratory‑developed test (LDT) — definition and regulatory context

DefinitionLaboratory-developed test (LDT): a test developed and validated by a laboratory and performed in‑house

Regulation (CLIA)LDTs are regulated by CMS under CLIA as high‑complexity tests

FDA statusLDTs are not approved or cleared by the U.S. FDA; FDA clearance is not currently required for clinical use

Documentation requirementLaboratory validation and CLIA high‑complexity status should be documented for claims involving LDTs

82746	Folic acid; serum.
82747	Folic acid; RBC.
0399U	Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG-binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected (Proprietary test: FRAT®; Lab/Manufacturer: Religen Inc)

OpenPayer

Folate Testing Coverage Policy

Coverage criteria — when folate testing is covered

Indications where testing may be covered

Tests and uses that do not meet coverage

Provider actions, documentation, and billing notes

What to include when ordering folate testing

Procedure codes

Recommended testing frequency

Definitions and test descriptions

Clinical background on folate